Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis
PaperCitations, authors & open-access status
Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 20 citations, 2015 year and green oa status.
20
Citations
2015
Year
green
OA Status